omicron variant inactivated covid-19 vaccine

The Omicron Variant Inactivated COVID-19 Vaccine is a monovalent, whole-virus inactivated vaccine developed by the Beijing Institute of Biological Products (BIBP), a subsidiary of Sinopharm's China National Biotec Group (CNBG). Specifically engineered to address the immune evasion characteristics of the SARS-CoV-2 Omicron variant, the vaccine is produced using the Vero cell platform. By utilizing an inactivated version of the Omicron strain, the vaccine presents the entire viral structure—including the mutated spike protein and other structural proteins like the nucleocapsid—to the immune system. This approach is intended to induce a broad neutralizing antibody response and T-cell immunity tailored to the Omicron lineage. The vaccine is typically formulated with an aluminum hydroxide adjuvant and is currently in early-stage clinical development (Phase 1) to evaluate its safety and immunogenicity as either a primary series or a booster dose.

Other names

Sinopharm Omicron vaccineBIBP Omicron-specific vaccineOmicron Variant Inactivated COVID-19 Vaccine (Vero Cell)